Dr. Lal PathLabs Ltd

Target overview

• Centrapath Labs Private Limited, healthcare/diagnostics services provider in India.
• Turnover: FY2024 20.8 Cr, FY2025 23.7 Cr, FY2026 20.5 Cr.
• Incorporated July 23, 2019; Indore, Madhya Pradesh.

Transaction details

• Remaining 30% equity stake in CPL acquired; CPL now wholly owned subsidiary of PUPL.
• Cash consideration; price per CPL share INR 1,608.352.
• Total cost of acquisition not disclosed.

Governance & approvals

• Not a related party transaction.
• Regulatory approvals: Not applicable.
• Completion status: Completed.

Rationale

• Acquire remaining stake to consolidate CPL as subsidiary under PathLabs Unifiers Private Limited.

Background

• CPL engaged in healthcare/diagnostics services; incorporated July 23, 2019; presence in Indore, Madhya Pradesh.

Acquisition details

• Target: Sunshine Healthcare Limited, Ghana; line of business not disclosed; sector not disclosed.
• Acquisition: 80% stake completed; SHL becomes a step-down subsidiary.
• Related party: not disclosed.
• Industry: Healthcare; sector not disclosed.
• Purpose/strategic rationale: not disclosed.
• Regulatory approvals: Regulation 30 LODR and SEBI circular.
• Timeline: Completed as of September 26, 2026.
• Consideration: not disclosed.
• Shareholding: 80% acquired.
• Background: SHL; products/services not disclosed; incorporation/turnover not disclosed.

Meeting Details

• Board meeting scheduled for November 04, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone and consolidated financial results for quarter and half-year ended Sep 30, 2026.

Other Notes

• Trading window closed Oct 01, 2026 to Nov 06, 2026 (inclusive).

Target overview

• Target: SN Genelab Private Limited, genomics diagnostics company incorporated Dec 16, 2013 in Gujarat, India.
• Turnover: FY2026 ₹57.96 crore; FY2025 ₹53.36 crore; FY2024 ₹43.27 crore.
• Acquisition: 70% stake for cash; up to ₹199.5 crore including earn-out.
• Post-acquisition SN Genelab Private Limited to become a Dr Lal PathLabs subsidiary.
• Completion target: by 30 November 2026.
• Not a related party transaction.
• Industry: Diagnostics - Genomics.
• Rationale: Strengthen genomics capabilities and broaden advanced diagnostics portfolio.
• Regulatory approvals: Not Applicable.
• Background: Incorporated 2013; genomics diagnostics; turnover history provided.

Acquisition details

• Target: Neuome Technologies Private Limited; sector not disclosed.
• Acquisition size: 30% stake subscription completed.
• Form of consideration: not disclosed.
• Acquirer: Dr. Lal Ventures Private Limited, a wholly owned subsidiary of Dr. Lal PathLabs.
• Relationship: related party transaction; Neuome becomes associate of the group.
• Completion date: August 27, 2026.
• Regulatory approvals: not disclosed.
• Strategic rationale: create associate relationship; outside core business not stated.
• Target background: products/services and incorporation date not disclosed.
• Turnover/size: not disclosed.

Uzbekistan subsidiary formation

• Dr Lal PathLabs FZCO subscribes to 70% of the newly incorporated entity in Uzbekistan.
• The subsidiary is named Dr Lal PathLabs Indomed LLC and is based in Tashkent.
• Dr Lal PathLabs FZCO will hold 70% of the subsidiary's share capital.
• Cash consideration will be paid at face value.
• Incorporation date of the subsidiary: August 19, 2026.
• The venture aims to strengthen the Group's diagnostics presence in Tashkent.
• Turnover for the entity is not applicable as it is newly incorporated.

Capital / Securities

• Board approved allotment of 211,050 ESOP shares under ESOP Plan 2022 on Aug 06, 2026.
• Paid-up equity capital increased to INR 1,67,84,88,200, comprising 16,78,48,820 shares of INR 10.

Financial Performance

• Revenue for Q1 FY27: Rs 798 crore, up 19.1% YoY.
• EBITDA: Rs 247 crore, margin 31.0%.
• PBT: Rs 229 crore, margin 28.7%.
• PAT: Rs 170 crore, margin 21.4%.
• EPS: Rs 10.1, up 27.8%.
• Revenue per patient: Rs 968, up 10%.
• Test per patient: 3.14, up from 3.07.
• Interim dividend declared: 50% (Rs 5 per share).
• Net cash and equivalents: Rs 1,693 crore as of June 30, 2026.

Operational Highlights

• Patient volumes: 8.2 million, up 8.2%.
• Samples: 25.9 million, up 10.7%.
• 116 new tests launched; 81 genomics assays; four first-in-India tests.
• SwasthAI WhatsApp bot launched to improve booking journeys.
• WES turnaround times: 15 days; Express WES: 10 days.
• Routine tests (~400) delivered in 3 hours for ~90% walk-ins.
• Dubai subsidiary incorporation marks international expansion milestone.

M&A and Capital Allocation

• Acquisition: 80% stake in Sunshine Healthcare Ltd, Ghana; cap not exceeding GHS 45.6 million.
• Acquisition: 30% stake in Neuome Technologies; Rs 3.5 crore.
• Cash deployment: primarily for M&A and high-end radiology centers.
• Capex guidance: Rs 140–150 crore for this year and next.
• Near-term international contribution not targeted; focus on Africa, Middle East, CIS, Southeast Asia.

Guidance and Outlook

• Q1 ahead of forecast; expects mid-teens revenue growth for FY27 after H1 review.
• CGHS uplift of 2-3% realized; likely continues 2-3 quarters.
• Pricing increase not planned in H1; reassessment at year-end.
• Swasthfit contribution near 20% remains; higher realization tests support.
• International contribution below 5%; improving gradually over 3-5 years.

Risks and Watchpoints

• Weather patterns affected Q1 volumes; impact uncertain for next quarters.
• Currency and inflation may raise material costs; realizations may offset margins.
• International expansion is longer-term with execution risk.

AGM Details

• AGM held 25 July 2026 at 10:00 IST via Video Conference/OAVM.
• Record date 18 July 2026.

Resolutions & Voting

• Resolution 1: Adopt financial statements; passed (99.87% in favour).
• Resolution 2: Final dividend of INR 4 per share; passed (100% in favour).
• Resolution 3: Appoint Rahul Sharma by rotation; passed (99.31% in favour).
• Resolution 4: Remuneration revision for Arvind Lal; passed (100%).
• Resolution 5: Remuneration revision for Vandana Lal; passed (100%).
• Resolution 6: Re-appoint Arvind Lal as Exec Chairman for 5 years from 2027; passed (99.80%).
• Resolution 7: Re-appoint Rajit Mehta as NED Independent for second term; passed (99.66%).
• Resolution 8: Remuneration to Rahul Sharma on ESOP exercise; passed (99.59%).
• Resolution 9: Payment of Commission to Non-Executive Directors; passed (99.99%).
• Resolution 10: Ratify Cost Auditors’ remuneration for 2026-27; passed (99.999%).

Dividend

• Final dividend of INR 4 per fully paid equity share approved.

Directors & Auditors

• Arvind Lal re-appointed as Executive Chairman for five years from 01-Apr-2027.
• Rajit Mehta re-appointed as Non-Executive Independent Director for a five-year term.
• Remuneration revisions approved for Arvind Lal and Vandana Lal.
• Cost Auditors’ remuneration for 2026-27 ratified.

Related Party & Other Approvals

• No material related party transactions disclosed.
• All other AGM approvals completed.